Hubei Biocause Heilen Pharmaceutical Co., Ltd.

SZSE:301211 Stock Report

Market Cap: CN¥6.0b

Hubei Biocause Heilen Pharmaceutical Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Qun Liang

Chief executive officer

CN¥404.2k

Total compensation

CEO salary percentagen/a
CEO tenure4.5yrs
CEO ownershipn/a
Management average tenure4.5yrs
Board average tenureno data

Recent management updates

Recent updates

Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings

Nov 04
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings

Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211) After Shares Rise 43%

Oct 30
Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211) After Shares Rise 43%

Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211)

Aug 07
Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211)

Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Will Pay A Larger Dividend Than Last Year At CN¥0.48

May 22
Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Will Pay A Larger Dividend Than Last Year At CN¥0.48

Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations

Apr 29
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations

CEO

Qun Liang (53 yo)

4.5yrs

Tenure

CN¥404,200

Compensation

Mr. Qun Liang is General Manager of Hubei Biocause Heilen Pharmaceutical Co., Ltd. from June 2020.

Leadership Team

NamePositionTenureCompensationOwnership
Qun Liang
General Manager4.5yrsCN¥404.20kno data
Ting Hao Yi
Financial Director4.5yrsCN¥396.70kno data
Jian Gao
Board Secretary2.6yrsCN¥402.10kno data
Zhenghua Huang
Deputy General Manager4.5yrsCN¥358.80kno data

4.5yrs

Average Tenure

51.5yo

Average Age

Experienced Management: 301211's management team is considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 23:06
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hubei Biocause Heilen Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution